Overview


According to FutureWise analysis the market for inhalational anesthesia drugs in 2023 is US$ 1.6 billion, and is expected to reach US$ 3.24 billion by 2031 at a CAGR of 9.26%.

Patients' healthcare costs can be reduced by inhaling anesthetics. Patients who have had surgery and are in critical condition are often admitted to ICUs. This increases healthcare costs because they are more likely to stay longer. Surgeons can use inhalation anesthesia to reduce the need for additional hospital stays. This is not possible with intravenous anesthesia, which reduces the patient's healthcare costs. Anesthesia drugs are used during surgical procedures to control blood pressure and breathing, pain, blood rate, rhythm, blood flow, blood flow, blood pressure, blood sugar, blood pressure, blood pressure, breathing, blood volume, and heart rate. Inhalational Anesthesia is a chemical compound that has anesthetic properties. It is used primarily for general anesthesia induction and sedation. These drugs can be administered via the use of a face mask and a tracheal tube that is attached to the vaporizer or another delivery method. Isoflurane, the most popular inhalation anesthesia drug, is extremely effective in low doses. It is preferred for patients with impaired liver function because it reduces the risk and passes through the lungs.

Inhalational anesthesia drugs can be used in the operating rooms for maintenance or induction. Because it is less likely to accumulate in the body, intravenous anesthesia has been preferred by physicians over inhalational anesthesia. Inhalational anesthesia drugs can be used in operating rooms for maintenance and induction. Because it is less likely to accumulate in the body, intravenous anesthesia has been preferred by physicians over inhalational anesthesia. Inhalational anesthesia drug administration can be used safely for patients who have multiple drug allergies. Anesthetic inhalation refers to a chemical compound that has anesthetic properties and can be inhaled through the body. The facemask, vaporizer-connected tube tracheal tube, and another delivery device control them. Anesthesia agents are used to control pain, respiration, and blood pressure during surgery. Inhalational anesthesia can be used for general anesthetics and sedation. Inhalational anesthetics are most frequently used with desflurane and sevoflurane. Inhalation anesthetics can cause respiratory depression, decreased blood pressure, cerebral metabolic demand, and increased blood circulation in the cerebrum. Nausea is the most common side effect of inhalation anesthesia.

Anesthetic agents are used during surgery to control blood pressure and heart rate. They also help with pain, blood flow, blood pressure, and breathing. Inhalational anesthesia is used to induction and maintain general anesthesia, as well as sedation for patients. Inhalational anesthetics tend to be preferred for maintenance purposes as they allow for more control over the anesthetic state and are generally less expensive. Inhalation anesthetics can be used in accident care. However, intravenous administration is difficult to select. Intubation of the trachea is used to quickly induce general anesthesia in emergency labor procedures. Except for nitrous oxide which causes an analgesic effect, inhalation anesthesia allows the appearance of amnesia and immobility. Inhalation anesthesia can cause nausea. It is caused by the inhalation of the gaseous, volatile anesthetic agent.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Inhalational Anesthesia Drugs Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Inhalational Anesthesia Drugs Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Halocarbon Products Corporation
  • Hikima Pharmaceuticals PLC
  • Lunan Pharmaceutical Group Co Ltd
  • Piramal Enterprises
  • Jiangsu Hengrui medicine Co Ltd
  • Fresenius Kabi AG
  • Abbvie Inc
  • Baxter International
  • Troikaa Pharmaceuticals Ltd

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Product Type

  • Sevoflurane
  • Isoflurane
  • Desflurane
  • Nitrous Oxide

By Application

  • Induction
  • Manintenance

By End User

  • Hospitals
  • Ambulatory Surgical Centers
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Inhalational Anesthesia Drugs Market By Product Type, By Application, By End User and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Inhalational Anesthesia Drugs Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Inhalational Anesthesia Drugs Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Inhalational Anesthesia Drugs Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Inhalational Anesthesia Drugs Market, By Product Type Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Sevoflurane
        2. Isoflurane
        3. Desflurane
        4. Nitrous Oxide

  • 8.   Inhalational Anesthesia Drugs Market, By Application Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Induction
        2. Manintenance

  • 9.   Inhalational Anesthesia Drugs Market, By End User Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Hospitals
        2. Ambulatory Surgical Centers
        3. Others

  • 10.   North America Inhalational Anesthesia Drugs Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2024-2032

  • 11.   Latin America Inhalational Anesthesia Drugs Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2024-2032

  • 12.   Europe Inhalational Anesthesia Drugs Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2024-2032

  • 13.   Asia Pacific Inhalational Anesthesia Drugs Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2024-2032

  • 14.   Middle East and Africa Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2024-2032

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Halocarbon Products Corporation
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Hikima Pharmaceuticals PLC
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Lunan Pharmaceutical Group Co Ltd
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Piramal Enterprises
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Jiangsu Hengrui medicine Co Ltd
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Fresenius Kabi AG
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Abbvie Inc
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Baxter International
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Troikaa Pharmaceuticals Ltd
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients